Business, energy, technology, markets and global industry news from Business News Today

Jinlin Hou

PharmaDeviceNews Jinlin Hou
Personalized neoantigen vaccines use tumor sequencing and computational prediction to identify patient-specific mutations, turning each cancer’s molecular fingerprint into a custom immunotherapy while putting speed, manufacturing and treatment-window logistics at the center of the challenge. Representative image.
Pharma & Biotech

Brii Bio’s hepatitis B strategy delivers 32.4% sustained HBsAg loss, but can it reach Phase 3?

Brii Bio reports 32.4% sustained HBsAg loss in ENRICH, while elebsiran supply uncertainty complicates the next phase of hepatitis B development.

Read More
Representative image: Laboratory researchers handle blood samples during chronic hepatitis B drug development, reflecting Brii Bio’s Phase 2b ENRICH and ENHANCE results for BRII-179, elebsiran and pegylated interferon alfa.
Pharma & Biotech

Could 16 weeks of AHB-137 change hepatitis B treatment? AusperBio reveals 15-month durability

AusperBio reports AHB-137 functional cure lasting up to 15 months off hepatitis B treatment, with larger trials needed to confirm durability.

Read More